Peptidsyntesemarked til $2,27 mia: Hvor specialister vinder

Peptidsyntesemarkedsnummeret er ikke et indkøbsinput

Før du behandler vækstdata som en leverandørdifferentiering, det er værd at undersøge, hvad de offentliggjorte tal faktisk måler - for de måler ikke det samme marked.

Grand View Researchs markedsanalyse for peptidsyntese anslået markedet til USD 961.5 million i 2024 og projekter USD 1.84 milliarder af 2033. Mordor Intelligence's 2026 markedsrapport for peptidsyntese placerer det samme marked på USD 1.90 milliard i 2026, på vej mod USD 2.59 milliarder af 2031. Rødder Analyse ankommer til USD 3.8 milliard for 2025. Fremtidig markedsindsigt udgiver USD 5.1 milliarder under en brugerdefineret definition af peptidsyntesetjenester. Alle disse dækker en periode inden for et par år efter hinanden.

Afvigelsen er ikke en uenighed om vækstrater. Det er et omfangsproblem. Tre forskellige niveauer af markedsdefinition giver tre ikke-sammenlignelige tal:

Ifølge Sammenhængende markedsindsigt' 2026 analyse, reagenser og forbrugsvarer alene repræsenterer 57.2% af det smallere produktvægtede marked. Fortune Business Insights melder tjenester kl 71.03% af en service-inkluderende ramme. Farmaceutisk fremstilling 2026 analyse af CDMO outsourcing bemærker det nogenlunde 55% af kompleks peptidudvikling er nu outsourcet til CDMO'er - hvilket netop er grunden til, at serviceniveauet puster tallet så dramatisk op i forhold til værktøjs-og-input-niveauet.

Den praktiske konsekvens: en køber, der læser en overskrift, kan ikke fortælle, om den beskriver de reagenser, der allerede er bestilt, kontraktsyntesetjenesten, der indkøbes, eller fremstillingsfasen tre år væk fra programmet. De $2.27 milliarder i overskriften er ét referencepunkt inde i dette opslag. Ethvert tal i det er en planlægningsfigur, ikke et leverandørevalueringsinput.

Markedsvækst gør én nyttig ting: det forklarer, hvorfor det bliver sværere at få adgang til de bedst positionerede specialiserede udbydere af peptidsyntese og peptidsyntese CDMO-partnere, ikke nemmere.

Lydhørhed: Den leverance, som koncentrationen ikke kan levere

Peptidsyntesemarkedet er moderat konsolideret i toppen. Mordor Intelligence's 2026 analyse placerer de fem bedste leverandører på anslået 55-60 % af den globale omsætning - et tal, der afspejler, hvordan kapital og kapacitet er akkumuleret ujævnt på trods af de overordnede væksttal. Specifikt til GLP-1 peptid API-segmentet, Global Market Insights semaglutid og tirzepatid API CDMO-analyse vurderer de fem bedste spillere - Bachem, PolyPeptide Group, CordenPharma, Lonza, og WuXi STA - på nogenlunde 80% dele.

En koncentration, der stiger i den grad, har en direkte konsekvens for ethvert program, der ikke er en af ​​de foretrukne konti i et niveau 1 CDMO. Kapacitetsudnyttelsen af ​​amerikansk peptid CDMO løb på omkring 78-85 % på tværs af etablerede producenter i midten af ​​2026, med fase 1 klinisk forsyningskapacitet estimeret til 82% gennemsnitlig udnyttelse på Tier 1 faciliteter. Den gennemsnitlige gennemløbstid fra kundekvalificering til første GMP-batch er udvidet til ca 14 måneder, op fra nogenlunde 9 måneder i 2023. Storskala SPPS-kapacitetsgennemløbstider rapporteres i intervallet 18-36 måneder.

Dette er efter mere end USD 3 milliarder i forpligtede anlægsudgifter i løbet af 2024-2026-cyklussen. De bindende begrænsninger er ikke reaktorantal, men input og infrastruktur: harpiksforsyning, beskyttet aminosyreforsyning, håndtering af opløsningsmidler og affaldshåndtering, lyofiliseringskapacitet, og knap proceskemi og QC-talent.

Hvad det betyder for købere: Selv på forskningsniveau, vendingen har ændret sig væsentligt. Tidslinjer for tilpasset peptidsyntese rapporterede at flytte fra 7-10 hverdage ind 2024 til minimum 3-4 uger pr 2026 efterhånden som testprotokollerne udvides. For et program med en specifik tidslinje til en screeningskampagne eller en IND-aktiverende undersøgelse, en 3-4 ugers baseline med Tier 1 udnyttelse ovenfor 80% er ikke det rigtige udgangspunkt.

Lydhørhed på det niveau, et program i forskningsfasen faktisk har brug for - adgang til projektforskere, rådgivning om modifikationsstrategi, hurtig iteration på vanskelige sekvenser — er netop, hvad store faciliteter optimeret til GMP-kampagner og kommercielle API har en tendens til at nedprioritere. Specialiserede udbydere, hvis pipeline ikke er domineret af GLP-1 API-produktion, kan operere med forskellig allokeringslogik.

Hvor denne dimension holder op med at betyde noget: for programmer i kommerciel skala med krav til kilogram til multikilogram, en Tier 1 CDMO's kapacitet og regulatoriske track record opvejer typisk ulempen ved responsivitet.

Vanskelige sekvenser: Hvor tilpasset peptidsyntesesuccesrate er produktet

Peptidsyntese Et renhedstal i et analysecertifikat registrerer, hvad der overlevede rensningstrinnet. Den registrerer ikke, hvad der gik tabt til den.

De primære urenhedsklasser i fastfasesyntese af vanskelige peptidsekvenser er trunkeringer, sletninger, racemiseringsprodukter, og oxidations- eller deamideringsmodifikationer. Den mest almindelige enkelt urenhedsklasse er deletion: når et koblingstrin svigter, og kæden ikke er lukket, den næste rest kan forlænge den forkerte sekvens med én position. Individuelle koblingsudbytter løber på omkring 99-99,8% pr. trin, hvilket betyder, at en kæde med 30 rester akkumulerer materialesletningsbyrde over dens syntese selv under velkontrollerede forhold. Hydrofobe og aggregeringstilbøjelige sekvenser forstærker dette: aggregering på harpiks reducerer kædetilgængeligheden, undertrykke reaktionseffektivitet på tværs af flere efterfølgende cyklusser og producere en rå profil, der kan indeholde 30% eller mere ikke-målmateriale selv før oprensning.

Rå peptid oprenses typisk ved præparativ omvendt fase HPLC, som fjerner de fleste deletions- og trunkeringsarter. Det er derfor en 98% endelig renhedsfigur og en rå renhedsfigur fra samme sekvens kan se helt forskellige ud fra hinanden. For en svær sekvens, det informative spørgsmål er ikke, hvad den endelige renhed er - det er, hvordan den rå profil så ud, hvad de vigtigste urenheder var, om de var karakteristiske, og hvilken brøkdel af råmaterialet der blev kasseret for at nå det endelige antal. En udbyder, der ikke kan eller vil dele den grove analytiske profil, beskriver ikke syntesen; den beskriver kun renselsen.

Beviser, som en køber bør anmode om:

• Rå HPLC-spor før oprensning, med identificerede urenheder på eller over 0.1%

• Præparative metodeforhold og skalaeffektivitet (hvilken brøkdel af råolie blev indvundet i den endelige pulje)

• Eventuelle sekvensspecifikke ændringer af standardkoblingsprotokollen (f.eks, dobbelt kobling, brug af et alternativt koblingsreagens til hindrede rester, temperaturkontrolleret harpiksbefugtning til strækninger, der er tilbøjelige til at samle sig)

• Reproducerbarhedsdata fra parti til parti, hvis mere end én syntesekampagne er blevet udført

Hvor denne dimension holder op med at betyde noget: for standard lineære sekvenser under 20 rester uden hydrofobe strækninger og uden usædvanlige modifikationer, de fleste udbydere med kompetent SPPS-infrastruktur vil opnå målrenheden ved første eller andet forsøg. Den svære sekvens dimension bliver bærende på eller over nogenlunde 25 rester, med stigende vægt for hvert hydrofobt plaster, disulfid bro, eller multi-site ændring.

MOL ændringer' tilpassede peptidsyntesetjenester beskrive en platform bygget specifikt til at adressere kompleks og vanskelig sekvenssyntese, spænder over fast fase, flydende fase, kombineret væske-faststof, omvendt fastfase, og mikrobielle fermenteringsruter - et kapacitetssæt, der betyder noget, fordi en enkelt-rute-butik vil nå sin grænse, før sekvensbesværet gør det.

Brugerdefinerede ændringer: Fra porteføljebredde til specifik reaktionsevne

Peptidmodifikationslandskabet har en vigtig lagdeling. En udbyder kan angive glykosylering, fosforylering, hæftede peptider, cykliske peptider, PEGylering, N-terminal og C-terminal modifikationer, FRET-mærkning, biotinylering, chelaterende peptider, og klik-kemihåndtag - og hver af de nævnte egenskaber kan betyde alt fra "vi har gjort dette en gang" til "vi har udviklet proceskemi til dette i milligram- og gramskala med analytisk verifikation."

Købers due diligence-spørgsmål er ikke, om en ændring er på menuen. Det er, om den specifikke kemi er bemandet, whether the provider’s team has executed your modification type at your target scale, and whether the QC protocol includes modification-specific verification beyond simple intact mass.

For a phosphopeptide, that means confirmation of the expected mass shift for phosphorylation (+79.96 Og) og, for a multi-site phosphorylation, an MS/MS fragmentation pattern that establishes which sites are modified. For a cyclic peptide with a side-chain lactam bridge, it means confirmation that the cyclisation is complete, that the linear precursor is absent or quantified, and that the ring geometry is as specified. For a PEGylated peptide, it means the PEG chain-length distribution is characterised.

Claims of “more than X modifications available” indicate portfolio breadth, which is necessary but not sufficient. The more diagnostic question is: for your specific modification, can the provider describe in advance which chemistry they will use, how they will confirm modification success analytically, and what their success-rate history looks like on that modification type?

MOL Changes offers over 300 modification base maps and a peptide modification and labelling service portfolio that spans the principal modification categories. For any specific project, the relevant evaluation is how the provider’s team will approach that modification technically — not the count.

Hvor denne dimension holder op med at betyde noget: for unmodified peptides or single-endpoint standard modifications (such as N-terminal acetylation or C-terminal amidation) on standard sequences, modification capability is table stakes at any serious provider.

Isotopmærkning: En niche, hvor positionel integritet er specifikationen

Isotope labelling is one of the dimensions where the gap between “we offer this” and “we can execute your project” is widest and most expensive to discover late.

Stable isotope labelled peptides — incorporating ¹³C, ¹⁵N, or deuterium (²H) — are used in absolute and relative protein quantitation by mass spectrometry (where a heavy-isotope peptide internal standard enables accurate determination of the light peptide analyte in a complex matrix), in structural NMR work on polypeptides too short to express recombinantly, and in metabolic-stability studies where deuterium at a known metabolic hotspot produces a measurable kinetic isotope effect.

Site-specific labelling imposes a more demanding specification than standard sequence synthesis. The label must be installed at the exact intended residue without scrambling to adjacent positions, without incomplete incorporation in the labelled fraction, and without unintended hydrogen–deuterium exchange at labile positions during synthesis or workup. A partially labelled population — whether from incomplete incorporation or from H/D back-exchange — shows up in the mass spectrum as envelope broadening: the observed isotope envelope is wider than the theoretical pattern for a fully labelled species, and the Δmass shift is smaller than expected.

For a deuterated peptide, the expected mass shift is approximately 1.006 Da per deuterium incorporated. If the measured shift is lower than that prediction, the labelling is incomplete. If the envelope width is inconsistent with a single labelled species, there is a mixed population. Both failures are detectable from a properly collected high-resolution MS dataset — if the provider generates one.

The expected verification package for a labelled peptide includes: isotopic enrichment or purity as a percentage; the observed isotope envelope; the calculated versus observed Δmass; high-resolution MS identity; og, where positional certainty is required, MS/MS fragmentation at the sequence level. For deuterium labelling specifically, NMR can supplement HRMS for positional assignment, though peptide NMR becomes progressively harder to interpret as length and complexity increase.

Providers who handle standard heavy reference peptides — typically ¹³C-Arg, ¹³C-Lys AQUA-grade material at the commodity end — often do not extend to custom site-specific labelling, mixed-isotope schemes, or deuterated sequences at non-standard positions. The demand is real, and the execution gap is real.

MOL Changes lists isotope labelled peptides — including custom site-specific deuterated and ¹³C/¹⁵N labelled formats — as a specific service category, distinct from standard fluorescent and biotin labelling, within a platform that spans click chemistry and chelating peptide conjugation.

Hvor denne dimension holder op med at betyde noget: for programs using standard heavy reference peptides (uniformly labelled ¹³C/¹⁵N on terminal residues) at research reagent quantities, the commercial catalogue now supports these adequately from multiple established vendors.

Analytisk dybde: Ud over renhedsprocenten

A certificate of analysis is an assurance document. A data package is a dataset. The two are not the same, and the distinction matters more in 2026 than it did in 2020.

EMA’s Vejledning om udvikling og fremstilling af syntetiske peptider — adopted by the CHMP in December 2025 and in effect since 1 juni 2026 — establishes that synthetic peptides are excluded from ICH Q3A, the standard impurity control framework for small molecules. Developers cannot transfer small-molecule impurity conventions to their peptide programs. I stedet, peptide-related impurities route through the European Pharmacopoeia: reported above 0.1%, identified above 0.5%, qualified above 1.0% — including in finished drug products. The guideline explicitly requires orthogonal analytical methods to avoid co-eluting impurities being missed by a single RP-HPLC method, and defines impurity control as a strategy rather than a number.

For a buyer evaluating a provider’s analytical capability, this regulatory context reframes what adequate data looks like. EN review of regulatory and analytical considerations for synthetic peptide quality published in the Journal of Pharmaceutical Investigation (2026) notes that structural identification by high-resolution mass spectrometry is expected for sequence-related impurities at or above 0.05% in drug substance specifications.

The purity-versus-content distinction is a practical corollary most quotations and COAs still obscure. HPLC area percent measures the proportion of UV-detected peak area attributable to the target peptide. Net peptide content by weight is a separate measurement. A peptide quoted at 98% HPLC purity can contain 70–85% actual peptide by mass because the vial also contains TFA counterion (residual from SPPS purification in acetonitrile-TFA mobile phases), vand, and residual solvents — none of which the HPLC area calculation subtracts. Two vendors quoting 98% may be delivering materially different quantities of actual peptide if their counterion burdens differ. Residual TFA at concentrations as low as 10 nanomolar has been reported to suppress cell proliferation in assay systems, so this is not a cosmetic detail for programs running cell-based screens.

A data package that enables an independent quality assessment includes:

• Lot-specific RP-HPLC chromatogram with method conditions (kolonne, mobile phase, gradient, detektionsbølgelængde) and identified impurities at or above 0.1%

• Orthogonal RP-HPLC on a second stationary-phase chemistry to expose co-eluting species

• HRMS identity with theoretical versus observed mass, specified as free base or salt form

• Amino acid analysis as an orthogonal compositional check

• Endotoxin quantified by LAL in EU/mg, not recorded as “not detected” — the relevant acceptance criteria for cell culture work is below 0.5 EU/mg, and for in vivo work is below 0.25 EU/mg

• Residual TFA and counterion identity

• Karl Fischer water content

• Net peptide content by an orthogonal Syntetiske peptider weight-based assay

MOL Changes maintains peptide testing and analytical services og quality management and documentation standards built on an ISO 9001:2015-aligned quality system, with customer audit rights as stated on the quality page — which is the baseline expectation for a program that will eventually need to demonstrate supplier qualification to a regulatory authority.

Hvor denne dimension holder op med at betyde noget: for discovery-phase reagents where a quick identity confirmation and approximate purity check serve the purpose, a full data package is overspecification. The analytical-depth dimension becomes binding as a program moves from in vitro screening toward cell-based or in vivo work where contamination profiles affect experimental outcomes.

Fleksibilitet på forskningsstadiet: Værdien, der forsvinder i skala

A peptide’s useful life in a research program spans several distinct demand states: a 5-milligram quantity for initial activity screening, a 50-milligram quantity for dose-finding, a 500-milligram quantity for PK studies, and a kilogram-range quantity for IND-enabling toxicology. Each crossing carries real discontinuity risk.

The discontinuities are chemical (process parameters optimised for gram-scale SPPS do not automatically transfer to kilogram-scale without revalidation), analytical (method development work at small scale needs to be repeated at each new scale with lot-specific analytical data), and organisational (different personnel, different facilities, different lead times). The organisational discontinuity is the one most often underestimated at the project-planning stage.

A provider who is only viable at the research-reagent scale creates a forced supplier switch at exactly the transition when the program is under the most schedule pressure. A provider who is only viable at commercial API scale is structurally uninterested in a 5-milligram discovery project and will price and prioritise accordingly.

Research-stage flexibility describes the ability to service a program continuously from first synthesis through pilot scale, with documented process understanding at each step. This is distinct from marketing “mg to kg capability” as a range. The operative question is: does the same team, using the same synthetic chemistry, carry the project through each scale transition — and if not, what formal tech transfer or handoff process applies?

The market structure reinforces why this dimension is at risk. Providers who have concentrated capacity on GLP-1 API and commercial-volume peptides — the segment where the most capital has flowed — are by construction not optimised for the hybrid service model that early-stage programs require.

What research-stage flexibility looks like in practice: the same project scientist works the sequence across milligram and gram scale; the research-grade synthesis report documents the deprotection and coupling conditions in a format that informs scale-up; the scale-up proposal references the research campaign explicitly and describes which parameters are being monitored for drift.

Hvor denne dimension holder op med at betyde noget: once a program has cleared IND-enabling studies and is procuring GMP campaign material, continuity from research synthesis is usually superseded by the GMP supplier’s own process development documentation, and research-stage flexibility becomes less relevant.

En seksdimensionel evalueringsramme

The following matrix summarises where each capability dimension matters most, what evidence to request, and when it can be deprioritised.

Hvad det betyder for programmer Valg af partner

Growth in the peptide synthesis market expands the addressable opportunity but concentrates the most capable capacity at the top of the market, where lead times are longest and programme prioritisation favours the largest accounts. This is not a temporary imbalance — the $3 billion+ capital expenditure cycle of 2024–2026 has not resolved it, because the bottlenecks are infrastructure and talent, not reactor area.

For a program working on a difficult sequence with a defined preclinical timeline, the practical consequence is that choosing a supplier on market position or scale alone is likely to produce disappointment at exactly the point when the sequence is hardest and the timeline is least flexible.

The six dimensions above are where differentiation is verifiable. They share a common structure: each has a specific evidence requirement that separates a capability claim from a capability demonstration. Portfolio breadth, facility class, and ISO certification are necessary but not sufficient. What the evidence requirements add is the ability to evaluate whether the specific competence needed for the specific project actually exists and is currently staffed.

Specialised providers who can demonstrate all six — responsiveness that holds even for research-stage programmes, analytical depth that extends to lot-specific orthogonal data and regulatory-grade impurity characterisation, and the continuity to carry a sequence through scale transitions — create value that no market-size figure describes or predicts.

If you are evaluating a synthesis partner for a program involving complex sequences, specific modifications, or scale transitions, the most productive starting point is a technical feasibility conversation — not a catalogue request. MOL Changes’ peptide synthesis platform, with Class 100 cleanroom production and a quality system aligned to ISO 9001:2015, is built for programmes that need all six of these dimensions addressed in one place.

Request a sequence-specific technical assessment or a lot-specific analytical data package through the custom peptide synthesis services page to begin the conversation on concrete ground.